GERMANTOWN, Md., July 22 /PRNewswire-FirstCall/ -- MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK), a pharmaceutical company focused on developing and commercializing novel anti-infective products, today announced that it has scheduled an investor conference call on Thursday, July 24, 2008 at 2:30 p.m. ET.

In light of MiddleBrook's recent announcement to conclude its strategic evaluation process with a $100 million investment from Equity Group Investments, L.L.C. (the EGI transaction), the Company has decided to host a public conference call to discuss the EGI transaction, provide a general corporate update, and introduce MiddleBrook's anticipated incoming executive management team. As was previously announced, should the EGI transaction close as expected, John Thievon will become MiddleBrook's president and chief executive officer, and David Becker will become the Company's executive vice president, finance and CFO.

Edward M. Rudnic, Ph.D., current MiddleBrook president and CEO, will host the Company's conference call at 2:30 PM ET on Thursday, July 24, 2008. John Thievon and David Becker will also participate on the call. There will be a question and answer period for investors following formal remarks.

Any person interested in participating in the conference call is welcome to join. To participate in the conference call, dial the appropriate number below shortly before the 2:30 PM start time and ask for the MiddleBrook Pharmaceuticals conference call hosted by Dr. Rudnic.

              The teleconference dial-in numbers are as follows:
                       Domestic callers 1-800-813-8504
                     International callers 1-706-643-7752
                       Conference ID number -- 57260493

The conference call will be 'live' only and the Company will not be providing a webcast or archiving of the conference call.

About Middlebrook Pharmaceuticals:

MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK) is a pharmaceutical company focused on the development and commercialization of anti-infective drug products that fulfill substantial unmet medical needs in the treatment of infectious disease. The Company is developing anti-infective drugs based on its novel biological finding that bacteria exposed to antibiotics in front-loaded staccato bursts, or 'pulses,' are killed more efficiently and effectively than those under standard treatment regimens. Based on this finding, MiddleBrook has developed a proprietary, once-a-day pulsatile delivery technology called PULSYS(R). The Company currently markets the Keflex(R) brand of cephalexin and has received regulatory approval for MOXATAG(TM) -- the first and only once-daily amoxicillin product approved for marketing in the U.S. For more on MiddleBrook, please visit http://www.middlebrookpharma.com.

SOURCE MiddleBrook Pharmaceuticals, Inc.